Dermapharm Holding SE
DMP
Rank in Stocks
#5706
Dermapharm Holding SE, alongside its group companies, specializes in the... Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Share Price
$43.04
Last synced: 2026-11-09
Market Cap
$2.13B
Change (1 day)
1.60%
Change (1 year)
9.75%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Dermapharm Holding SE (DMP)
Category
Healthcare
EPS for Dermapharm Holding SE (DMP)
EPS as of June 2026 TTM: $3.09
According to Dermapharm Holding SE's latest financial reports, its current EPS (TTM) is $3.09. At the end of 2025 the company had an EPS of $2.89, an increase over its 2024 EPS of $2.20.
EPS history for Dermapharm Holding SE from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $3.09 | 6.89% |
| 2025 | $2.89 | 31.45% |
| 2024 | $2.20 | 71.22% |
| 2023 | $1.28 | -51.99% |
| 2022 | $2.67 | -39.62% |
| 2021 | $4.42 | 128.44% |
| 2020 | $1.94 | 20.69% |
| 2019 | $1.60 | -0.98% |
| 2018 | $1.62 | -13.44% |
| 2017 | $1.87 | 15.52% |
| 2016 | $1.62 | 521.80% |
| 2015 | $0.26 | -20,146.15% |
| 2014 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 110.47% |
DE
|
|
| $6.08 | 96.75% |
DE
|
|
| $1.55 | -49.80% |
JP
|
|
| $3.66 | 18.48% |
CH
|
|
| $0.45 | -85.43% |
IL
|
Questions about Dermapharm Holding SE's earnings per share (EPS)
What is Dermapharm Holding SE's earnings per share (EPS)?
Dermapharm Holding SE's earnings per share (EPS) over the last twelve months is $3.09, as of Jun 2026.
What was Dermapharm Holding SE's earnings per share (EPS) in 2025?
In 2025, Dermapharm Holding SE's earnings per share (EPS) was $2.89, 31.36% more than in 2024 ($2.20).
How has Dermapharm Holding SE's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Dermapharm Holding SE's earnings per share (EPS) went from $1.94 to $2.89, an average growth of 8.30% a year.
How does Dermapharm Holding SE's earnings per share (EPS) compare with similar companies?
Dermapharm Holding SE's earnings per share (EPS) ($3.09) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.